# Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)

> **NCT04016714** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1191 (actual)

## Conditions studied

- Pneumococcal Infections

## Interventions

- **DRUG:** V114
- **DRUG:** Prevenar 13™
- **DRUG:** Vaxelis™
- **DRUG:** M-M-R®II
- **DRUG:** VARIVAX™

## Key facts

- **NCT ID:** NCT04016714
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-28
- **Primary completion:** 2021-10-29
- **Final completion:** 2021-10-29
- **Target enrollment:** 1191 (ACTUAL)
- **Last updated:** 2023-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04016714

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04016714, "Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04016714. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*